UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Proteomic profiling of a patient with cutaneous melanoma metastasis regression following topical contact sensitizer diphencyprone and immune checkpoint inhibitor treatment

Scientific reports, 2022-12, Vol.12 (1), p.22364-22364, Article 22364

2022

Volltextzugriff (PDF)

Modulation of Inflammatory Proteins in Serum May Reflect Cutaneous Immune Responses in Cancer Immunotherapy

JID innovations, 2023-03, Vol.3 (2), p.100179, Article 100179

2023

Volltextzugriff (PDF)

Skin proteomic analysis of immune activation associated with regression of melanoma metastases induced by diphencyprone

JAAD international, 2022-12, Vol.9, p.65-68

2022

Volltextzugriff (PDF)

Mouse Models of Itch

Journal of investigative dermatology, 2024-09

2024

Volltextzugriff (PDF)

40704 Dupilumab treats lenalidomide-associated rashes and plays a potentially tumor-suppressive role in multiple myeloma patients

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB151-AB151

2023

Volltextzugriff (PDF)

Use of dynamic optical coherence tomography in a corticosteroid vasoconstrictor assay: a pilot study

International journal of dermatology, 2023-07, Vol.62 (7), p.e414-e416

2023

Volltextzugriff (PDF)

A worthwhile tool in evaluating worrisome lesions

The Journal of Family Practice, 2023-09, Vol.72 (7), p.E1-E22

Owji, Shayan

2023

Volltextzugriff (PDF)

Dupilumab in Multiple Myeloma: A Case Series

Clinical lymphoma, myeloma and leukemia, 2022-12, Vol.22 (12), p.928-932

2022

Volltextzugriff (PDF)

Dupilumab to treat drug reaction with eosinophilia and systemic symptoms: A case series

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2023-12, Vol.11 (12), p.3789-3791

2023

Volltextzugriff (PDF)

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

The New England journal of medicine, 2016-12, Vol.375 (24), p.2335-2348

2016

Volltextzugriff (PDF)

CLA + memory T cells in atopic dermatitis: CLA+ T cells and atopic dermatitis

Allergy (Copenhagen), 2024-01, Vol.79 (1), p.15-25

2024

Volltextzugriff (PDF)

The impact of dupilumab treatment on SARS‐CoV‐2 T cell responses in atopic dermatitis patients

Allergy (Copenhagen), 2023-02, Vol.78 (2), p.571-574

2023

Volltextzugriff (PDF)

The erythema Q‐score, an imaging biomarker for redness in skin inflammation

Experimental dermatology, 2021-03, Vol.30 (3), p.377-383

2021

Volltextzugriff (PDF)

CLA+ memory T cells in atopic dermatitis

Allergy (Copenhagen), 2024-01, Vol.79 (1), p.15-25

2024

Volltextzugriff (PDF)

Targeting IL‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years

Allergy (Copenhagen), 2024-06, Vol.79 (6), p.1560-1572

2024

Volltextzugriff (PDF)

Molecular signatures order the potency of topically applied anti-inflammatory drugs in patients with atopic dermatitis

Journal of allergy and clinical immunology, 2017-10, Vol.140 (4), p.1032-1042.e13

2017

Volltextzugriff (PDF)

Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)

Journal of the American Academy of Dermatology, 2021-07, Vol.85 (1), p.62-70

2021

Volltextzugriff (PDF)

Alopecia areata exhibits cutaneous and systemic OX 40 activation across atopic backgrounds

Allergy (Copenhagen), 2024-08

2024

Volltextzugriff (PDF)

Alopecia areata exhibits cutaneous and systemic OX40 activation across atopic backgrounds

Allergy (Copenhagen), 2024-08

2024

Volltextzugriff (PDF)

Targeting IL‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2years

Allergy (Copenhagen), 2024-06, Vol.79 (6), p.1560-1572

2024

Volltextzugriff (PDF)

The atopic dermatitis spectrum disorder. Recognizing the clinical heterogeneity in patients with atopic related skin conditions in order to improve therapeutic decision-making and outcomes: an expert panel consensus statement

The Journal of dermatological treatment, 2022-05, Vol.33 (4), p.2397-2399

2022

Volltextzugriff (PDF)

Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery

Nature medicine, 2022-04, Vol.28 (4), p.626-629

2022

Volltextzugriff (PDF)

Use of 308 nm excimer laser for the treatment of chronic hand and foot eczema

International journal of dermatology, 2016-08, Vol.55 (8), p.e447-e453

2016

Volltextzugriff (PDF)

Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery

Nature medicine, 2022-08, Vol.28 (8), p.1723-1723

2022

Volltextzugriff (PDF)

Cover Image

Experimental dermatology, 2021-03, Vol.30 (3)

2021

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Proteomic profiling of a patient with cutaneous melanoma metastasis regression following topical contact sensitizer diphencyprone and immune checkpoint inhibitor treatment

Modulation of Inflammatory Proteins in Serum May Reflect Cutaneous Immune Responses in Cancer Immunotherapy

Skin proteomic analysis of immune activation associated with regression of melanoma metastases induced by diphencyprone

Mouse Models of Itch

40704 Dupilumab treats lenalidomide-associated rashes and plays a potentially tumor-suppressive role in multiple myeloma patients

Use of dynamic optical coherence tomography in a corticosteroid vasoconstrictor assay: a pilot study

A worthwhile tool in evaluating worrisome lesions

Dupilumab in Multiple Myeloma: A Case Series

Dupilumab to treat drug reaction with eosinophilia and systemic symptoms: A case series

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

CLA + memory T cells in atopic dermatitis: CLA+ T cells and atopic dermatitis

The impact of dupilumab treatment on SARS‐CoV‐2 T cell responses in atopic dermatitis patients

The erythema Q‐score, an imaging biomarker for redness in skin inflammation

CLA+ memory T cells in atopic dermatitis

Targeting IL‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years

Molecular signatures order the potency of topically applied anti-inflammatory drugs in patients with atopic dermatitis

Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)

Alopecia areata exhibits cutaneous and systemic OX 40 activation across atopic backgrounds

Alopecia areata exhibits cutaneous and systemic OX40 activation across atopic backgrounds

Targeting IL‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2years

The atopic dermatitis spectrum disorder. Recognizing the clinical heterogeneity in patients with atopic related skin conditions in order to improve therapeutic decision-making and outcomes: an expert panel consensus statement

Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery

Use of 308 nm excimer laser for the treatment of chronic hand and foot eczema

Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery

Cover Image

Suchergebnisse filtern